The revolutionary PROPEL mini sinus stent, offered at New York-Presbyterian Weill Cornell, recently received expanded FDA approval to help improve results of sinus surgery for those suffering from chronic sinus conditions.
PROPEL mini sinus stent
New York, New York– Lane Krevitt, MD a NY Presbyterian Weill Cornell surgeon is one of the first in New York City to use the innovative PROPEL mini sinus stent for people who suffer from chronic disease of the frontal sinuses, which are located in the forehead area.
The PROPEL mini sinus stent is a dissolvable, drug-releasing technology that Dr. Krevitt inserts at the end of sinus surgery. The spring-like device helps prop open the sinus airway after the surgery and gradually delivers anti-inflammatory medicine to the sinus lining, right where it’s needed. The stent is designed to dissolve within 45 days, so removal isn’t necessary.
PROPEL mini was previously approved by the FDA to treat ethmoid sinuses, which are located between the eyes. Recently, PROPEL mini received FDA approval to treat the sinuses located in the forehead area, allowing even more patients to potentially benefit from this technology. Patients who received PROPEL mini after sinus surgery needed fewer post-operative procedures and needed less oral steroids1,2.
“The PROPEL mini stent keeps the sinus open and gives us another tool to reduce the likelihood of the sinus becoming blocked again after surgery,” said Dr. Lane Krevitt of the New York Otolaryngology Group . “This stent targets the sinuses with a sustained release of medicine to help the sinuses heal, then dissolves away. As a result of PROPEL mini’s new approval, even more patients can receive this important technology.”
Dr. Krevitt has been using the PROPEL mini sinus stent since 2013 and has seen positive results in his patients. After sinus surgery and placement of PROPEL mini, patients may breathe easier and ultimately find sinus relief.
About Chronic Sinus Disease
Chronic sinus disease is a condition in which sinuses become swollen and inflamed, leading to difficulty breathing, facial pain, headache and loss of sense of smell and taste. The condition is often misdiagnosed as allergies or a “never ending cold” and greatly impacts a person’s quality of life.
Dr. Krevitt noted chronic sinusitis is prevalent in the NYC area. “Propel provides a way to treat the sinus not only immediately after surgery but also continues to treat post operatively”
1 Han JK, Marple BF, Smith TL et al. Int Forum Allergy Rhinol. 2012; 2:271-279.
2 PROGRESS Study data as outlined in PROPEL mini Instructions For Use.
The PROPEL sinus implant is intended for use following ethmoid sinus surgery to maintain patency. PROPEL mini is intended for use following ethmoid or frontal sinus surgery to maintain patency. The implants are intended for use in patients ≥18 years of age. Contraindications include patients with intolerance to mometasone furoate (MF) or a hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females has not been studied. Risks may include pain/pressure, displacement of implant, and possible side effects of intranasal MF. The most common adverse events in clinical studies were sinusitis, headache, epistaxis and bronchitis. For complete prescribing information see IFU at www.PROPELOPENS.com. Rx only.
PROPEL is a trademark and registered trademark of Intersect ENT, Inc.